|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Cash and due from banks | |||||||||||||||||||
| Interest-bearing deposits | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Investment securities available for sale | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Investment securities available for sale | |||||||||||||||||||
| Other investments | |||||||||||||||||||
| Total securities | |||||||||||||||||||
| Mortgage loans held for sale | |||||||||||||||||||
| Loans | |||||||||||||||||||
| Less allowance for credit losses | |||||||||||||||||||
| Net loans | |||||||||||||||||||
| Premises and equipment, net | |||||||||||||||||||
| Cash surrender value of life insurance | |||||||||||||||||||
| Other real estate | |||||||||||||||||||
| Right of use lease asset | |||||||||||||||||||
| Accrued interest receivable and other assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| Deposits: | |||||||||||||||||||
| Noninterest-bearing demand | |||||||||||||||||||
| Interest-bearing demand, MMDA & savings | |||||||||||||||||||
| Time, over $250,000 | |||||||||||||||||||
| Time, $250,000 and over | |||||||||||||||||||
| Other time | |||||||||||||||||||
| Total deposits | |||||||||||||||||||
| Securities sold under agreements to repurchase | |||||||||||||||||||
| Junior subordinated debentures | |||||||||||||||||||
| Lease liability | |||||||||||||||||||
| Lease liability | |||||||||||||||||||
| Accrued interest payable and other liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Commitments and Contingencies | |||||||||||||||||||
| Shareholders' equity: | |||||||||||||||||||
| Preferred stock, no par value; authorized 5,000,000 shares; no shares issued and outstanding | |||||||||||||||||||
| Common stock, no par value; authorized 20,000,000 shares; issued and outstanding 5,461,490 shares at June 30, 2026 and 5,459,441 shares at December 31, 2025 | |||||||||||||||||||
| Common stock held by deferred compensation trust, at cost; 164,970 shares at March 31, 2024 and 158,356 shares at December 31, 2023 | |||||||||||||||||||
| Common stock held by deferred compensation trust, at cost; 150,423 shares at September 30, 2025 and 158,580 shares at December 31, 2024 | |||||||||||||||||||
| Common stock held by deferred compensation trust, at cost; 140,163 shares at June 30, 2026 and 150,288 shares at December 31, 2025 | |||||||||||||||||||
| Deferred compensation | |||||||||||||||||||
| Retained earnings | |||||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||||
| Total shareholders' equity | |||||||||||||||||||
| Total liabilities and shareholders' equity | |||||||||||||||||||
Loading...
